Miranda, Marissa C.
HRN: 22-07-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/24/2022
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
10/24/2022
10/31/2022
IV
750mg
OD
CAP-MR
Waiting Final Action
Indication: Empirical Escalation Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes